Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Alternative Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal mouse IgG2a, kappa
Application Bioactivity-ELISA
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to vascular endothelial growth factor (VEGF). DC101 is a monoclonal antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor angiogenesis, tumor proliferation and metastasis, and affect the activity of cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Alternative Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal mouse IgG2a, kappa
Application Bioactivity-ELISA
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to vascular endothelial growth factor (VEGF). DC101 is a monoclonal antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor angiogenesis, tumor proliferation and metastasis, and affect the activity of cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
